Sign In
Buy AWH
$0.0820
+0 (+0%)
At Close: Jul 30, 2025
Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
08:00am, Tuesday, 09'th Apr 2024
Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, a
Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript
11:37am, Thursday, 28'th Mar 2024
Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript
Aspira Women's Health Reports Fourth Quarter and Full Year 2023 Financial Results
07:30am, Thursday, 28'th Mar 2024
2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter an
Aspira Women's Health to Present at the MedInvest Biotech & Pharma Investor Conference
08:00am, Thursday, 21'st Mar 2024
AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development
Aspira Women's Health to Present at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
08:30am, Thursday, 22'nd Feb 2024
AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development
AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic diseas
AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development
Aspira Women's Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
08:00am, Thursday, 14'th Dec 2023
AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the developme
Aspira Women's Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
08:00am, Wednesday, 06'th Dec 2023
Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma
Aspira Women's Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)
08:00am, Tuesday, 28'th Nov 2023
California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)
09:47am, Monday, 27'th Nov 2023
CMS approves OvaWatch SM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical
Aspira Women's Health Inc. (AWH) Q3 2023 Earnings Call Transcript
07:37pm, Monday, 13'th Nov 2023
Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2023 Earnings Call November 13, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financi
The proposed rule would allow for OvaWatch SM to be reimbursed at the same rate as Ova1 ® at $897 per test and will become final following a brief public comment period
Aspira Women's Health to Present at the BioVenture Nexus Conference
08:00am, Friday, 29'th Sep 2023
The conference is taking place on October 5-6, 2023, in Los Angeles, CA The conference is taking place on October 5-6, 2023, in Los Angeles, CA
